Intracranial Outcomes of 1L Selpercatinib in Advanced RET fusion-positive (RET plus ) NSCLC: LIBRETTO-431 study

被引：0
|
作者：
Perol, Maurice [1 ]
Solomon, Ben J. [2 ]
Goto, Koichi [3 ]
Park, Keunchil [4 ]
Nadal, Ernest [5 ]
Bria, Emilio [6 ]
Martin, Claudio [7 ]
Bar, Jair [8 ]
Williams, Justin [9 ]
Puri, Tarun [9 ]
Li, Jian [10 ]
Uh, Minji [9 ]
Lin, Boris [9 ]
Zhou, Caicun [11 ]
Pruthi, Aarohan [9 ]
机构：
[1] Ctr Leon Berard, Lyon, France
[2] Peter MacCallum Canc Inst, Melbourne, Vic, Australia
[3] Natl Canc Ctr Hosp East, Chiba, Japan
[4] Samsung Med Ctr, Seoul, South Korea
[5] Inst Catala Oncol, Barcelona, Spain
[6] Fdn Policlin Univ Agostino Gemelli IRCCS, Rome, Italy
[7] Inst Alexander Fleming, Buenos Aires, DF, Argentina
[8] Sheba Med Ctr, Inst Oncol, Ramat Gan, Israel
[9] Eli Lilly, Indianapolis, IN USA
[10] Loxo Lilly, Indianapolis, IN USA
[11] Shanghai Pulm Hosp, Shanghai, Peoples R China
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
259
引用
收藏
页码：138 / 138
页数：1
相关论文
共 50 条
  • [31] Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes
    Lu, Chang
    Wei, Xue-Wu
    Zhang, Yi-Chen
    Chen, Zhi-Hong
    Xu, Chong-Rui
    Zheng, Ming-Ying
    Yang, Jin-Ji
    Zhang, Xu-Chao
    Zhou, Qing
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (07) : 2987 - 2995
  • [32] Updated overall efficacy and safety of selpercatinib in patients with RET fusion-positive non-small-cell lung cancer (NSCLC): LIBRETTO-001 study
    Besse, B.
    Drillon, A. E.
    Solomon, B. J.
    Subbiah, V.
    Tan, D. S. -W.
    Park, K.
    De Braud, F. G.
    Alonso, G.
    Wolf, J.
    Soldatenkova, V.
    Lin, A. K.
    French, P.
    Goto, K.
    Gautschi, O.
    SWISS MEDICAL WEEKLY, 2021, 151 : 34 - 34
  • [33] Efficacy and Safety of Selpercatinib (LOXO-292) in East Asian Patients with RET Fusion-Positive NSCLC
    Loong, H.
    Goto, K.
    Park, K.
    Ohe, Y.
    Nishio, M.
    Cho, B. C.
    Kim, Y. J.
    French, P.
    Soldatenkova, V.
    Tan, D.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S231 - S232
  • [34] Intracranial Activity of Selpercatinib in Chinese Patients With Advanced RET Fusion-Positive Non-Small-Cell Lung Cancer in the Phase II LIBRETTO-321 Trial
    Cheng, Ying
    Huang, Dingzhi
    Zhou, Jianying
    Zhou, Chengzhi
    Sun, Yuping
    Wu, Lin
    Guo, Ye
    Shao, Jingxin
    Zhang, Wanli
    Lu, Shun
    JCO PRECISION ONCOLOGY, 2023, 7
  • [35] Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) patients on the LIBRETTO-001 trial.
    Subbiah, Vivek
    Gainor, Justin F.
    Oxnard, Geoffrey R.
    Tan, Daniel Shao-Weng
    Owen, Dwight Hall
    Cho, Byoung Chul
    Loong, Herbert H. F.
    McCoach, Caroline Elizabeth
    Weiss, Jared
    Kim, YuJung
    Bazhenova, Lyudmila
    Park, Keunchil
    Daga, Haruko
    Besse, Benjamin
    Gautschi, Oliver
    Ng, Sarah
    Huang, Xin
    Drilon, Alexander E.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [36] Randomized phase 3 study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC
    Loong, Herbert
    Goto, Koichi
    Solomon, Benjamin
    Park, Keunchil
    Perol, Maurice
    Arriola, Edurne
    Novello, Silvia
    Cheng, Ying
    Ardizzoni, Andrea
    Mak, Milena
    Santini, Fernando
    Elamin, Yasir
    Drilon, Alexander
    Wolf, Juergen
    Han, Baohui
    Han, Hongmei
    Uh, Minji
    Puri, Tarun
    Soldatenkova, Viktoriya
    Zhou, Caicun
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 246 - 246
  • [37] Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC
    Loong, H. H. F.
    Goto, K.
    Solomon, B. J.
    Park, K.
    Perol, M.
    Arriola, E.
    Novello, S.
    Cheng, Y.
    Ardizzoni, A.
    Mak, M.
    Santini, F. C.
    Elamin, Y. Y.
    Drilon, A.
    Wolf, J.
    Han, B.
    Han, H.
    Uh, M.
    Puri, T.
    Ilaria, V.
    Zhou, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S1303 - S1303
  • [38] Case report: Selpercatinib in the treatment of RET fusion-positive advanced lung adenocarcinoma: a challenging clinical case
    Pagliaro, Raffaella
    Medusa, Paola Maria
    Vitiello, Fabiana
    Aronne, Luigi
    Campbell, Susan F. M.
    Perrotta, Fabio
    Bianco, Andrea
    FRONTIERS IN ONCOLOGY, 2025, 14
  • [39] Clinicopathologic features of advanced RET fusion-positive lung cancers and outcomes in comparison to other fusion-positive lung cancers
    Drilon, Alexander E.
    Hellmann, Matthew David
    Wang, Lu
    Cho, Eun Jung
    Ladanyi, Marc
    Rizvi, Naiyer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [40] LIBRETTO-001 cohort 7: A single-arm, phase 2 study of neoadjuvant selpercatinib in patients with resectable stage IB-IIIA RET fusion-positive NSCLC.
    Rajaram, Ravi
    Sholl, Lynette M.
    Dacic, Sanja
    Goldman, Jonathan W.
    Tan, Daniel Shao-Weng
    Gautschi, Oliver
    Loong, Herbert H. F.
    De Braud, Filippo G.
    Massarelli, Erminia
    Levy, Benjamin Philip
    Dy, Grace K.
    Kang, Suhyun
    Szymczak, Sylwia
    Chao, Bo H.
    Drilon, Alexander E.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345